会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 21. 发明申请
    • Albumin-Fused Anti-Angiogenesis Peptides
    • 白蛋白融合抗血管生成肽
    • US20120263747A1
    • 2012-10-18
    • US13285727
    • 2011-10-31
    • Peter MertinsIlhan CelikOliver KiskerDarrell SleepJoanna HayHans-Peter Hauser
    • Peter MertinsIlhan CelikOliver KiskerDarrell SleepJoanna HayHans-Peter Hauser
    • C07K19/00A61P9/10A61P9/00A61K39/385A61K48/00A61P37/04A61P29/00A61P19/02A61P17/06A61P27/02A61P1/00A61P17/00A61P17/02A61P1/04A61K38/38
    • A61K38/39A01K2217/05A61K9/0019A61K31/7088A61K38/00A61K39/00A61K39/0005A61K47/643A61K48/00A61K2039/53C07K14/005C07K14/47C07K14/765C07K14/78C07K14/8114C07K2319/00C07K2319/31C12N15/62C12N2740/16122C12Y301/26003
    • The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor aniogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis.
    • 本发明涉及包含血管生成抑制肽(例如内皮抑素肽(包括但不限于其片段和变体))的蛋白质,其表现出与白蛋白融合或缀合的抗逆转录病毒活性(包括但不限于片段或变体 的白蛋白)。 这些融合蛋白在本文中统称为白蛋白融合蛋白。 这些融合蛋白在本文中统称为白蛋白融合蛋白。 这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白,组合物,药物组合物,制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体,用这些核酸和载体转化的宿主细胞,以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ,载体和/或宿主细胞。 本发明还涉及抑制血管内皮细胞增殖和肿瘤发生生成诱导的细胞融合的组合物和方法。 本发明还涉及预防原发性肿瘤和转移瘤的生长或促进消退的组合物和方法; 并用于治疗癌症,糖尿病性视网膜病变,进行性黄斑变性或类风湿性关节炎。
    • 22. 发明申请
    • Albumin-Fused Kunitz Domain Peptides
    • 白蛋白融合Kunitz结构域肽
    • US20110092413A1
    • 2011-04-21
    • US12917903
    • 2010-11-02
    • Hans-Peter HauserThomas WeimerVal RombergScott M. KeeDarrell SleepRobert Charles LadnerArthur C. Ley
    • Hans-Peter HauserThomas WeimerVal RombergScott M. KeeDarrell SleepRobert Charles LadnerArthur C. Ley
    • C07K14/76A61K38/38A61P11/00C12N15/62C12N15/63C12N1/00C12P21/02
    • C12N15/62C07K2319/31
    • The invention relates to proteins comprising serine protease inhibiting peptides, such as Kunitz domain peptides (including, but not limited to, fragments and variants thereof) fused to albumin, or fragments or variants thereof. These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules and vectors encoding the albumin fusion proteins of the invention, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting neutrophil elastase, kallikrein, and plasmin. The invention further relates to compositions and methods for treating cystic fibrosis and cancer.
    • 本发明涉及包含丝氨酸蛋白酶抑制肽的蛋白质,例如与白蛋白或其片段或变体融合的Kunitz结构域肽(包括但不限于其片段和变体)。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白,组合物,药物组合物,制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白,用这些核酸和载体转化的宿主细胞的核酸分子和载体,以及使用这些核酸,载体和/或宿主制备本发明的白蛋白融合蛋白的方法 细胞。 本发明还涉及抑制嗜中性粒细胞弹性蛋白酶,激肽释放酶和纤溶酶的组合物和方法。 本发明还涉及治疗囊性纤维化和癌症的组合物和方法。
    • 23. 发明申请
    • Interleukin-11 Fusion Proteins
    • 白细胞介素-11融合蛋白
    • US20100143973A1
    • 2010-06-10
    • US12626107
    • 2009-11-25
    • Monika KrözGerhard DickneiteHans-Peter HauserThomas WeimerDarrell Sleep
    • Monika KrözGerhard DickneiteHans-Peter HauserThomas WeimerDarrell Sleep
    • C07K19/00C12P21/00C12N5/10C12N1/21C12N1/15C12N1/19C12N15/63C07H21/04C07K14/54
    • A61K38/38A61K38/2073C07K14/5431C07K14/76C07K14/765C07K2319/31Y02A50/473
    • The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or anti-inflammatory properties, fused to albumin (including, but not limited to, fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention”. These fusion proteins exhibit extended shelf-life and/or pharmacokinetic properties and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases.
    • 本发明涉及包含白细胞介素11(IL-11)(包括但不限于其片段和变体)的蛋白质,其表现出与白蛋白融合的血小板生成或抗炎特性(包括但不限于片段或变体 的白蛋白)。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白具有延长的保质期和/或药代动力学性质和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白,组合物,药物组合物,制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体,用这些核酸和载体转化的宿主细胞,以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ,载体和/或宿主细胞。 本发明还涉及用于治疗或预防血小板减少症或炎性疾病的组合物和方法。
    • 27. 发明申请
    • Albumin-fused kunitz domain peptides
    • 白蛋白融合kunitz结构域肽
    • US20050222023A1
    • 2005-10-06
    • US10503834
    • 2003-02-07
    • Hans-Peter HauserThomas WeimerVal RombergScott KeeDarrell SleepRobert LadnerArthur Ley
    • Hans-Peter HauserThomas WeimerVal RombergScott KeeDarrell SleepRobert LadnerArthur Ley
    • C07K14/675C12N15/62
    • C12N15/62C07K2319/31
    • The invention relates to proteins comprising serine protease inhibiting peptides, such as Kunitz domain peptides (including, but not limited to, fragments and variants thereof) fused to albumin, or fragments or variants thereof. These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses, therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting neutrophil elastase, kallikrein, and plasmin. The invention further relates to compositions and methods for treating cystic fibrosis and cancer.
    • 本发明涉及包含丝氨酸蛋白酶抑制肽的蛋白质,例如与白蛋白或其片段或变体融合的Kunitz结构域肽(包括但不限于其片段和变体)。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白,组合物,药物组合物,制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体,用这些核酸和载体转化的宿主细胞,以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ,载体和/或宿主细胞。 本发明还涉及抑制嗜中性粒细胞弹性蛋白酶,激肽释放酶和纤溶酶的组合物和方法。 本发明还涉及治疗囊性纤维化和癌症的组合物和方法。
    • 29. 发明申请
    • Interleukin-11 Fusion Proteins
    • 白细胞介素-11融合蛋白
    • US20120258072A1
    • 2012-10-11
    • US13278757
    • 2011-10-21
    • Monika KrözGerhard DickneiteHans-Peter HauserThomas WeimerDarrell Sleep
    • Monika KrözGerhard DickneiteHans-Peter HauserThomas WeimerDarrell Sleep
    • C07K19/00A61P7/02A61P1/00C12N5/10C12P21/02C12N15/63C12N1/19A61K38/20C12N15/62
    • A61K38/38A61K38/2073C07K14/5431C07K14/76C07K14/765C07K2319/31Y02A50/473
    • The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or anti-inflammatory properties, fused to albumin (including, but not limited to, fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention”. These fusion proteins exhibit extended shelf-life and/or pharmacokinetic properties and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases.
    • 本发明涉及包含白细胞介素11(IL-11)(包括但不限于其片段和变体)的蛋白质,其表现出与白蛋白融合的血小板生成或抗炎特性(包括但不限于片段或变体 的白蛋白)。 这些融合蛋白在本文中统称为白蛋白融合蛋白。 这些融合蛋白具有延长的保质期和/或药代动力学性质和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白,组合物,药物组合物,制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子,以及含有这些核酸的载体,用这些核酸和载体转化的宿主细胞,以及使用这些核酸制备本发明的白蛋白融合蛋白的方法, 载体和/或宿主细胞。 本发明还涉及用于治疗或预防血小板减少症或炎性疾病的组合物和方法。